REG - BSF Enterprise PLC - Director/PDMR Shareholding

BSF EnterpriseAnnouncement

14/06/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240614:nRSN5268Sa&default-theme=true

RNS Number : 5268S  BSF Enterprise PLC  14 June 2024

 

14 June 2024

BSF Enterprise PLC

("BSF" or the "Company")

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS

 

BSF (LSE: BSFA), (OTCQB: BSFAF), has received notification from its Director
Geoff Baker being a person discharging managerial responsibilities, of the
purchase of shares as set out in the notification of dealing form here:
https://bsfenterprise.com/wp-content/uploads/2024/06/PDMR_Notification.pdf
(https://bsfenterprise.com/wp-content/uploads/2024/06/PDMR_Notification.pdf)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                              0207 186 9000

 Isabella Pierre                          0207 186 9927

 SEC Newgate (Financial Communications)

 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 George Esmond

 

 

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

 

Notes to Editors

 

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions to deliver sustainable materials and products
across a variety of sectors. BSF Enterprise's core technology platform in
industrial tissue engineering allows the manufacture at scale of lab-grown
alternatives to animal and human tissues, helping deliver sustainable products
and materials of the future. The Company's technologies have multiple
applications across consumer and medical markets including lab-grown leather,
cultivated meat, human corneas and in vitro animal models.

 

BSF owns 100% of pioneering UK-based tissue engineering companies 3D
Bio-Tissues (3DBT), that successfully produced the UK's first high-quality
cultivated meat and lab-grown skin from its laboratory and Kerato, a developer
of lab-grown corneal replacement tissue for medical and research uses. In
addition, it owns 100% of BSF Enterprise (Hong Kong) Limited which is actively
supporting commercialisation of our technology in China and Asia.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation and expansion of the Groups IP, which has multiple
applications, as well as through M&A. BSF aims to build a comprehensive
portfolio in tissue engineering and related applications and license out IP to
various stakeholders in the supply chain to enable manufacture at scale and
achieve widespread market penetration.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKZLBFZQLZBBQ